Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
Date:3/7/2013

$9.8 million and $20.1 million, respectively.  This compares with $1.2 million and $5.5 million, respectively, in the same periods in 2011. The increase in 2012 compared to 2011 was due to an increase in revenue earned through the Company's strategic collaboration with Teva, as a result of the clinical development activities associated with the AFFINITY trial which was initiated in August 2012. Revenue for 2012 included recognition of $18.3 million from the $30.0 million upfront payment, as well as $1.8 million earned through collaborative research.
  • At December 31, 2012, the $30.0 million advanced reimbursement received from Teva in December 2009 was fully expended resulting in a Current Deferred Collaboration Revenue balance of zero.  Teva is required to fund all additional expenses under the Amended Clinical Development Plan.
  • Total operating expenses for the fourth quarter and year ended December 31, 2012 increased to $16.0 million and $46.0 million, respectively, compared with $9.2 million and $27.8 million, respectively, in the same periods in 2011. The increase in 2012 as compared to 2011 was due primarily to higher clinical study expenses associated with the start-up of the AFFINITY trial, increased patient enrollment in the Borealis-1 trial, OGX-427 manufacturing costs and increased employee expenses, including stock-based compensation expense.  These increases were partially offset by lower preclinical expenses.  Included in operating expenses for the fourth quarter and year ended December 31, 2012 was a $1.7 million restructuring gain related to revised assumptions used to estimate the value of the Company's excess lease liability.
  • Net loss for the fourth quarter and year ended December 31, 2012 was $4.1 million, or $0.28 per diluted common share, and $21.1 million, or $1.56 per diluted common share, respectively. Net loss for the fourth quarter and year ended December 31, 2011 was $9.6 million, or $0.
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    3. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/23/2014)...  Aurobindo Pharma USA is ... mg 100-count bottles to the consumer level. The product ... Empty capsules could result in missed dose(s) ... range from no effect, short term reduction in efficacy, ... seizures) that could be life-threatening. Aurobindo Pharma ...
    (Date:11/22/2014)... MIAMI , Nov. 22, 2014  New data ... for the most common form of female sexual dysfunction, ... cognitive function or driving performance in premenopausal women when ... Sexual Medicine Society of North America,s ... Miami . SMSNA accepted ...
    (Date:11/22/2014)... noviembre de 2014  BioClinica®, Inc., un proveedor ... tecnologías eClinical, ha indicado un aumento de la ... el seguimiento basado en el riesgo en los ... del seguimiento basado en el riesgo más allá ... seguimiento o cambio de los métodos de seguimiento. ...
    Breaking Medicine Technology:Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
    ... June 1, 2011 Esperance ... of a $7.5 million Series B financing. Proceeds from ... EP-100, the lead cancer-targeting drug candidate from Esperance,s Cationic ... of the Company,s pipeline. Sanofi led the Series B ...
    ... June 1, 2011 MMRGlobal, Inc. (OTCBB: ... www.deutsch-boerse.com ) have entered into an agreement ... health IT products and services, including MMRPro for healthcare ... Health Record (PHR) ( www.mmrvideos.com ), on the ...
    Cached Medicine Technology:Esperance Pharmaceuticals Completes $7.5 Million Series B Financing 2VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 2VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 3VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 4VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 5
    (Date:11/24/2014)... California (PRWEB) November 24, 2014 ... USD 6.19 billion by 2020, according to a ... incidence rates of cardiac arrhythmias clubbed with growing ... of this market. Though still in the budding ... significant rise in usage rates in the recent ...
    (Date:11/24/2014)... CHICAGO (PRWEB) November 24, 2014 ... VolparaAnalytics version 1.2 at the 100th Annual Meeting ... November 30-December 5, 2014 (RSNA Booth 1752 – ... version of VolparaAnalytics and the rest of its ... VolparaDensity and VolparaDoseRT, which enable personalized measurements of ...
    (Date:11/24/2014)... Virginia (PRWEB) November 24, 2014 Residents ... center stage in this year’s SENIORS GOT TALENT, an ... Guide. , From piano players to classic crooners, to ... clear that older adults are indeed living young. , ... competition because there’s a cash prize, has always been ...
    (Date:11/24/2014)... Olaparib functions as a chemical of ... one of the first PARP inhibitors. Sufferers with BRCA1/2 ... of melanoma, and are often immune to other types ... malignancies a exclusive weaknesses, as the tissues of melanoma ... and allow them to proceed splitting. This implies that ...
    (Date:11/24/2014)... York (PRWEB) November 24, 2014 The ... by the Family and Children's Association to ... as soap, shampoo, mouthwash and other such items.The Association's ... who are home bound, living in nursing homes, assisted ... to greatly enhance the well being of seniors throughout ...
    Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3
    ... the latest study by the Mayo clinic, injecting an anesthetic ... ,The new study that is being presented today ... the American Urological Association, in San Diego, had found that ... of pain during their biopsy. It was explained that the ...
    ... disease of the rich and comfortably off in India has now ... classes in India.// , The disease has become so ... with the diabetic population in the country reaching a count of ... to more than double. ,International attention has been drawn ...
    ... caused drastic increase in cancer among kids across Europe. They ... cases of cancer in kids identified between 1978 and 1997 ... to the results, there was an increase by an average ... in children under the age of 14. ,Majority ...
    ... According to a review that was published in the Friday’s issue ... reduce their risk of fractures in the later years.// ... got by the age of 18 years. Hence, it is expected ... effects of age-related bone loss and osteoporosis. ,The results ...
    ... used to treat migraine headaches can be effective in ... zolmitriptan targets nerves that carry pain signals, Dr. Peter ... said.// ,Cluster headaches are not as common as ... 92 patients with cluster headaches. In the final analysis ...
    ... wells near the Queen’s Balmoral Castle in Scotland kills cancer ... biochemistry at the University of Maribor in Slovenia said that ... and compared them to those placed in normal lab water. ... of colon cancer cells 62.5 percent more quickly than normal ...
    Cached Medicine News:Health News:India’s Silent Killer on the Prow 2Health News:17 percent rise in childhood cancer cases due to modern lifestyles 2
    CTAD tubes contain theophylline, adenosine and dipyridamol. Coagulation and DTAD tubes are for examination of coagulation parameters....
    ... tubes contain a buffered sodium ... with a citrate concentration of ... mol/l (3.8%). The mixing ratio ... to 9 parts blood. In ...
    Inquire...
    Inquire...
    Medicine Products: